CD6/CTLA-4 CAR-Treg / PTG-007+ / rituximab

About Immuthera

Immuthera is a U.S.-based, wholly-owned subsidiary of Poland's PolTREG S.A., established to advance Tregulatory cell therapies in the American market. Its core asset is a licensed, first-in-class CD6/CTLA-4 CAR-Treg platform initially developed at City of Hope, with prior clinical evaluation in chronic refractory GvHD. The company aims to build a broad pipeline for autoimmune diseases by leveraging its parent company's clinical experience and pursuing partnerships for next-generation technologies, including mRNA/LNP-based in vivo Treg generation.

Therapeutic Areas